

Prevalence of antibiotic resistance in *Escherichia coli* strains simultaneously isolated from humans, animals, food, and the environment: a systematic review and meta-analysis

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Ali Pormohammad¹
Mohammad Javad Nasiri²
Taher Azimi^{2,3}

¹Student Research Committee, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

²Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

³Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Background: Antimicrobial resistance is a serious public health problem worldwide. We aimed to investigate the prevalence of antibiotic resistance in *Escherichia coli* strains simultaneously isolated from humans, animals, food, and the environment.

Methods: Studies on PubMed, Embase, and the Cochrane Library published from January 1, 2000 to January 1, 2018 were searched. The quality of the included studies was assessed by the modified critical appraisal checklist recommended by the Joanna Briggs Institute. All analyses were conducted using Biostat's Comprehensive Meta-Analysis version 2.0. Depending on the heterogeneity test for each antibiotic, we used a random- or fixed-effect model for pooled prevalence of drug resistance. Studies were eligible if they had investigated and reported resistance in two or more isolation sources (human, animal, food, or environment). To decrease heterogeneity and bias, we excluded studies that had reported *E. coli* drug resistance isolated from one source only. We included publications that reported drug resistance with minimum inhibitory concentration or disk diffusion method (DDM) as antibiotic-susceptibility tests.

Results: Of the 39 included studies, 20 used the DDM and 19 minimum inhibitory concentration for their antibiotic-susceptibility testing. Colistin had the lowest prevalence, with 0.8% (95% CI 0.2%–3.8%) and amoxicillin the highest, with 70.5% (95% CI 57.5%–81%) in isolated human *E. coli* strains tested with the DDM. To assess historical changes in antimicrobial drug resistance, subgroup analysis from 2000 to 2018 showed a significant increase in ciprofloxacin resistance.

Conclusion: Monitoring and evaluating antibiotic-sensitivity patterns and preparation of reliable antibiotic strategies may lead to better outcomes for inhibition and control of *E. coli* infections in different regions of the world.

Keywords: antibiotic, drug resistance, *Escherichia coli*

Introduction

Antimicrobial resistance is a serious public health problem worldwide.^{1–3} Inappropriate use of antibiotics by humans, factories, and farms, poor hygiene and sanitation, and inefficient prevention and control of infections in health-care settings are considered important reasons in the emergence and distribution of antibiotic-resistant bacteria.^{4,5} Extended-spectrum β -lactamases (ESBLs) are enzymes that confer resistance to most β -lactam antibiotics, including penicillins, cephalosporins, and

Correspondence: Taher Azimi
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, PO Box 15468-15514, Tehran, Iran
Tel +98 938 213 0411
Email Taherazimi5@gmail.com

the monobactam aztreonam. Infections with ESBL-producing organisms have been associated with poor outcomes.⁶ An important example of antibiotic resistance is multidrug-resistant (MDR) and ESBL-producing *Escherichia coli*, which can cause life-threatening infections.⁷ *E. coli* is the predominant facultative flora in the gastrointestinal tract of humans and animals.⁸ Some *E. coli* strains, however, have developed the ability to cause disease in the gastrointestinal, urinary, and central nervous systems.^{9,10} Prolonged exposure of *E. coli* to antibiotics contributes to the development of antibiotic resistance.^{11,12} Thus, antibiotic-resistant bacteria, including *E. coli*, in animals could serve as important reservoirs for colonization and infection in human beings.⁸ Research has indicated that drug-resistant *E. coli* can be transmitted to human beings from the environment through direct or indirect contact (eg, consumption of contaminated food and water).¹¹ Therefore, assessing the prevalence of drug-resistant *E. coli* in different sources is critical for establishing guidelines in veterinary and human health care. To this end, we conducted a systematic review and meta-analysis to investigate the prevalence of antibiotic resistance in *E. coli* strains simultaneously isolated from humans, animals, food, and the environment.

Methods

Sources of information and search strategies

For papers from January 1, 2000 to January 1, 2018, PubMed, Embase, and the Cochrane Library were searched with the MeSH terms “*Escherichia coli*”, “drug resistance”, “antimicrobial resistance”, “animal”, “environment”, and “food”. These terms were combined with text searches that included “*E. coli*”, “antibiotic(s)”, “Gram-negative bacteria”, “Enterobacteriaceae”, “*Escherichia*”, “antibiotic resistance”, “antibacterial drug”, and “meat”. Contact was made with expert authors by mail to request any details not included in the original publications and unpublished work regarding our previous experiences.^{13–15} In addition, we searched related reviews and references for relevant studies. We conducted our study according to PRISMA guidelines.¹⁶

Eligibility

Inclusion criteria

Two reviewers (TA and AP) independently carried out a review on titles and abstracts and chose those fitting the selection criteria for full-text evaluation. Discrepancies were

discussed with a third reviewer (MJM). All original articles in the English language that simultaneously reported the prevalence of antibiotic resistance in *E. coli* strains isolated from humans, animals, the environment, and food with standard laboratory tests were included. Studies were eligible if they reported the prevalence of drug resistance in *E. coli* base on laboratory-standard guidelines. We considered all standard guidelines for inclusion in the study: Clinical and Laboratory Standards Institute (CLSI), National Committee for Clinical Laboratory Standards (NCCLS), Committee of the French Society of Microbiology, European Committee on Antimicrobial Susceptibility (EUCAST), British Standard for Antimicrobial Chemotherapy. However, only CLSI/NCCLS and EUCAST guidelines were used in all included studies.

Standard laboratory tests included disk diffusion method (DDM), minimum inhibitory concentration (MIC), and E. test. The aim of this study was to investigate the prevalence of drug-resistant *E. coli* strains from different sources and compare them with one another. As such, we included publications pursuing a common goal that reported the prevalence of drug resistance in *E. coli* from different sources. To decrease heterogeneity and bias, we excluded studies that reported *E. coli* drug resistance isolated from one source only. In this study, MDR strains were defined as resistant to three or more antimicrobial classes.

Data extraction and data collection

Data extracted were name of first author, publication date, sample size, time and location of study, total number of analyzed *E. coli* strains, and number of drug-resistant *E. coli* strains. Data were independently collected by two authors (AP and TA).

Exclusion criteria

Articles excluded were those that had not used standard methods (according to guidelines) for detection of drug resistance, had not reported the sample size, or had inappropriate data. Due to limited papers, we excluded studies that reported with Vitek (n=2), plate/replicator (n=1), Isosensitest (n=1), and Trek Diagnostic Systems products (n=1) for prevention of methodological bias (Figure 1). Furthermore, to reduce any potential heterogeneity that might be caused by different laboratory producers and quality of antibiotics, studies that reported the prevalence of antibiotic resistance from different sources (human, animal and environment) separately were excluded.




Figure 1 Flow diagram of literature search and study selection.

Quality assessment

Quality assessment of the studies were performed by two reviewers independently, according to the modified critical appraisal checklist recommended by the Joanna Briggs Institute.¹⁷ Disagreements were resolved by a consensus-based discussion. The checklist is composed of seven questions (question 4 has two scores) that reviewers answer for each study. The “Yes” answer for each question receives 1 point. Final scores for each study can range from 0 to 8 (Table S1).

Meta-analysis approach

All statistical analyses were carried out with Comprehensive Meta-Analysis version 2.0 (Biostat, Englewood, NJ, USA). Determination of the heterogeneity of studies was carried out using both chi-squared (Cochran’s Q) and I^2 tests to assess the appropriateness of pooling data. Depending on the heterogeneity test, we used

a random- or fixed-effect model for the pooled prevalence of drug resistance. In cases of high heterogeneity ($I^2 > 50\%$), the random-effect model (Mantel–Haenszel

heterogeneity) was used, and for low heterogeneity ($I^2 < 50\%$), the fixed-effect model was used.¹⁸ Begg’s and Egger’s tests were used to assess publication bias. Point estimation of effect size, prevalence, and 95% CIs were measured for each study.

Ethics statement

There was a systematic review, so ethical approval was not required.

Results

Selection of studies

A total of 39 studies, selected from a total of 28,489 articles (0.137%, 39 of 28,489) found in the initial search, were included in the final analysis. The location of studies

Table 1 Characterization of included studies

Study	Time enrolled	Published	Country	Isolate source	Method	Interpret Guidelines	Sample
Adhiratha et al ⁵	2012–2013	2014	Thailand	Humans, animals, food/environment	ADM	NOT	Stool samples, water samples collected from canals, fish and shrimp ponds- Rectal swabs, cooked food
Alali et al ¹⁹	2004–2006	2008	USA	Food/environment, animals	ADM	CLSI	Human wastewater, swine fecal
Alexandra et al ²¹	2011	2014	Portugal	Food/environment, humans	ADM	CLSI	Fecal, beach and waste waters
Kazemnia et al ²²	2012	2014	Iran	Humans, animals	DDM	CLSI	Urine samples, poultry carcasses
Azucena et al ²³	1992–1999	2005	Spain	Humans, animals, food/environment	DDM	NOT	Feces sample, food, beef meat
Baoguang et al ^{3,24}	2012–2014	2018	China	Humans, animals	BMD	CLSI	Blood, rectal swab
Bhoomika et al ³	2014–2015	2016	India	Humans, animals, food/environment	DDM	CLSI	Urine and stool- Chicken meat, Chevron meat, Raw milk
Bogaard et al ²⁵	NS	2001	Netherlands	Humans, animals, food/environment	ADM	NOT	Feces sample, sample from slaughterers
Hanna et al ²⁶	2000–2001	2006	Australia	Humans, animals, food/environment	DDM	CLSI	Rectal swabs- environmental swabs
Iuliana et al ²⁷	2011–2012	2015	United Kingdom	Humans, animals	DDM	CLSI	Fecal samples
James ²⁸	2002–2004	2007	USA	Humans, animals	ADM	CLSI	Fecal sample- meat of chicken
James et al ^{29,*}	1998–2001	2003	USA	Humans, animals	ADM	CLSI	Intestinal and Extra intestinal sample
Wang et al ³⁰	2011–2013	2017	China	Humans, animals, food/environment	DDM	CLSI	Urine and fecal- food sample
Joanne et al ³¹	2007–2009	2010	Australia	Humans, animals	DDM	CLSI	Urine- animal specimen
Jorge et al ³²	2009–2010	2013	Sweden	Humans, animals	DDM	CLSI	Fecal samples
Karen et al ³³	NS	2011	USA	Animals, food/ environment	DDM	CLSI	Feces sample, Wastewater
Katherine et al ³⁴	2007–2008	2009	USA	Humans, animals	DDM	CLSI	Fecal swab specimen
Krushna et al ⁸	2010–2011	2012	Sweden	Humans, animals, food/environment	DDM	CLSI	Stool samples, cow-dung, drinking water
Wang et al ³⁵	1997–2009	2017	China	Humans, animals, food/environment	DDM	NOT	Fecal/diarrhea -cattle and swine feces-food sample
Purohit et al ³⁶	2015	2017	India	Humans, animals, food/environment	DDM	NOT	Stool- waste, drinking water
Sannes et al ³⁷	1998–1999	2004	USA	Humans, animals	DDM	CLSI	Urine-feces
Miles et al ³⁸	2000–2001	2006	Jamaica	Humans, animals	DDM	CLSI	Urine and wound specimens of hospitalized patients- fecal samples of broiler chickens
Sabate et al ³⁹	2005	2008	Spain	Humans, animals, food/environment	DDM	CLSI	Human and animal wastewater

(Continued)

Table I (Continued).

Study	Time enrolled	Published	Country	Isolate source	Method	Interpret Guidelines	Sample
Dhaka et al ⁴⁰	2014–2016	2016	India	Humans, animals, food/environment	DDM	NOT	Stool- diarrhea - food and environmental samples
Pasquali et al ⁴¹	NS	2015	Italy	Humans, animals	ADM	CLSI	NOT
Ross et al ⁴²	2014–2016	2016	USA	Humans, animals	ADM	CLSI	Urine, semen and wound swabs-raw sewage, aeration tank with activated sludge, and final effluent without disinfection
Koczura et al ⁴³	2008–2009	2012	Poland	Humans, food/ environment	DDM	CLSI	Human septage - Animal fecal- Surface water, Farm environment
Sayah et al ⁴⁴	2002–2003	2005	USA	Humans, animals, food/environment	DDM	CLSI	Human fecal sample- swine fecal sample
Scott et al ⁴⁵	2003–2004	2005	USA	Humans, animals	BMD	CLSI	Urine, cervix, vagina and prostate, and blood, pus and wounds-feces sample
Seputiene et al ⁴⁶	2005–2008	2010	Lithuania	Humans, animals	DDM	CLSI	Meat- feces or liver samples
Tao et al ⁴⁷	2007–2008	2010	China	Food/environment, animals	ADM	CLSI	Stool samples
Tatsuya et al ⁴⁸	2006–2008	2010	South Korea	Humans, animals	ADM	CLSI	Stool- Feces
Tatsuya et al ⁴⁹	2008	2011	South Korea	Humans, animals	ADM	CLSI	Birds fecal sample- surface and waste waters
Thomas et al ⁵⁰	2002	2005	Canada	Food/environment, animals	ADM	NOT	Fecal samples-Caeca and food sample
Thorstein et al ⁵¹	2006–2007	2008	Iceland	Humans, animals	BMD	CLSI	Urine specimens- kidneys with chronic and / or acute lesions
Viktoria et al ⁵²	2008	2009	Denmark	Humans, animals	ADM	CLSI	Urine, blood- intestinal biopsy samples, feces
Winokur et al ⁵³	1998–1999	2001	USA	Humans, animals	BMD	CLSI	Fecal, urine, blood, wound- fecal samples- food such as Hamburger, sausage and minced, chicken, Skin of chicken, Caecum of chicken, Breast of chicken, Pre-cooked chicken foods, Turkey products
Yolanda et al ⁵⁴	1997–1999	2001	Spain	Humans, animals, food/environment	ADM	CLSI	Clinical and Stool samples-large intestine
Young et al ⁵⁵	2001–2003	2005	Korea	Humans, animals	ADM	CLSI	

Abbreviations: ADM, agar dilution method; DDM, disk diffusion method; BMD, broth microdilution; NS, not specified.

Table 2. Prevalence of antibiotic resistance in human, animal, food/environment *E. coli* isolates with Disk Diffusion method

Antibiotic	HUMAN ISOLATES				ANIMAL ISOLATES				FOOD/ENVIRONMENT ISOLATES			
	% PP (CI 95%)	n/N	N of study	i^2 (%P)	% PP (CI 95%)	n/N	N of study	i^2 (%P)	% PP (CI 95%)	n/N	N of study	i^2 (%P)
CL	0.8 (0.2-3.8)	1/217	2	0.54	10 (1-45)	31/193	2	0.12	3.2 (0.1-63.3)	10/204	2	0.005
CIP	28.3 (17.2-42.7)	161/607	11	< 0.001	18.3 (5.7-50)	169/1039	8	< 0.001	14.4 (5.4-33.4)	152/555	7	< 0.001
TMP	16 (10-25)	123/697	3	0.001	9.2 (2.3-30)	92/784	3	< 0.001	24 (15-36.7)	14/58	1	1
SMZ	28.5 (25.5-33)	133/469	3	0.35	22.2 (9.8-43)	338/1596	3	< 0.001	21.3 (4.6-6)	49/314	2	< 0.001
CF	33.5 (16-57)	552/1078	7	< 0.001	17.5 (5.8-42.2)	401/1937	5	< 0.001	33.6 (13-63)	256/543	4	< 0.001
AK	2 (0.2-16.5)	10/355	3	< 0.004	1.8 (0.3-10)	8/707	3	0.03	4 (1.2-13.4)	10/262	3	0.05
AUG	2 (1.1-3.7)	10/597	6	0	1.5 (0.8-3)	8/637	3	0.2	4.8 (1.7-13)	3	2	0.73
AMX	70.5 (57.5-81)	41/58	2	0	96 (76-99)	24/25	1	1	58.4 (51.7-65)	125/214	1	1
CFX	5.5 (1.6-16.7)	98/1141	6	< 0.001	6.2 (5-47.2)	97/852	5	< 0.001	3.4 (1-11)	2/73	2	0.94
CTX	58 (52.3-63.6)	171/294	4	0.2	58 (16.5-90.5)	140/308	4	< 0.001	31.15 (16.3-52)	97/433	4	< 0.001
CHL	12.5 (6-25)	38/305	7	0.002	3 (1-8.5)	40/1629	3	< 0.001	10 (3-27.8)	93/592	5	< 0.001
CRO	3.3 (1-10)	2/187	3	0.2	0.2 (0-1.7)	0/592	2	0.34	1.6 (0.2-10.7)	0/73	2	0.54
IMP	2.7 (1.4-5)	7/634	6	0.15	0.9 (0.3-2.8)	1/833	5	0.17	2.7 (1.5-4.7)	10/431	4	0.57
SXT	27.6 (11-54.3)	580/1336	9	< 0.001	30 (7.7-69)	410/2170	9	< 0.001	25.8 (8-57.7)	109/597	7	< 0.001
TET	54.6 (37.3-71)	711/1192	13	< 0.001	53 (36-69.5)	861/2201	10	< 0.001	47 (25-70)	338/811	8	< 0.001
GM	21.5 (12.5-34.5)	329/1173	12	< 0.001	13.6 (5.6-29.4)	149/947	6	< 0.001	9 (3.223)	105/796	7	< 0.001

(Continued)

Table 2. (Continued).

Antibiotic	HUMAN ISOLATES				ANIMAL ISOLATES				FOOD/ENVIRONMENT ISOLATES			
	% PP (CI 95%)	n /N	N of study	I ² (%P)	% PP (CI 95%)	n/N	N of study	I ² (%P)	% PP (CI 95%)	n/N	N of study	I ² (%P)
KAN	51 (15.2-85.7)	85/253	4	< 0.001	6.2 (4.4-8.7)	32/514	1	1	30.4 (1.4-93)	155/272	2	< 0.001
NA	32 (12.3-61)	161/468	9	< 0.001	21.4 (2-80)	132/1765	6	< 0.001	8.5 (2.8-22.7)	31/473	2	0.004
AMP	49.7 (35.3-64)	556/1211	14	< 0.001	44.4 (19-73)	443/2190	10	< 0.001	40.2 (16.5-69.5)	322/811	8	< 0.001
CAZ	49.2 (32-66.7)	106/204	3	0.007	57.4 (23-97)	85/111	2	< 0.001	10 (3.8-24.4)	36/358	2	0.003
STR	39.7 (30.3-50)	172/458	4	0.03	30.5 (15-52.4)	44/1938	5	< 0.001	28.4 (10.7-56.8)	74/363	3	< 0.001
MDR	22 (5.2-58.6)	475/1310	4	< 0.001	5.7 (3.3-9.6)	13/249	3	0.18	31.3 (24-33.3)	45/144	1	1
ESBL	13 (2-52.7)	77/211	4	< 0.001	26.3 (6-66.5)	73/287	3	< 0.001	25 (18.6-32.7)	36/144	1	1

Abbreviations: MDR, Multidrug Resistant; ESBL, Extended Spectrum β -lactamase; PP, Pooled prevalence; n or N, Number; PP, Pooled prevalence; CL, Colistin; CIP, Ciprofloxacin; TMP, trimethoprim; SMZ, Sulfisoxazole; CF, Cephalothin; AK, Amikacin; AUG, Amoxicillin-clavulanic acid; AMX, amoxicillin; CFX, Cefoxitin; CTX, Cefotaxime; CHL, Chloramphenicol; CRO, Ceftriaxone; IMP, Imipenem; SXT, Trimethoprim-sulfamethoxazole; TET, Tetracycline; GM, Gentamicin; KAN, kanamycin; NA, Nalidixic acid; AMP, Ampicillin; CAZ, Ceftazidime; STR, Streptomycin.




Figure 2 Prevalence of antibiotic resistance in human, animal, food/environment *E. coli* isolates with disk diffusion method.

covered east to west and north to south of the world, with the majority of patients from the US, China, and India. Each assessment with more than one isolation source was treated as a separate study. Figure 1 shows the selection process. Characteristics of the selected articles are summarized in Table 1. Of the 39 included studies, 20 used the DDM, 15 agar dilution, and four broth microdilution as the antibiotic-susceptibility test. Some studies used agar dilution and broth dilution combined, referred to as MIC testing for the analysis. In the included studies, 20 studies simultaneously reported prevalence data in humans and animals, 13 in humans, animals, food, and the environment, five in animals, food, and the environment and one in human, food, and the environment.

Prevalence of antibiotic resistance in *E. coli* isolates using DDM

Prevalence of different antibiotic resistance in *E. coli* strains isolated from humans is shown in Figure 2, Table 2, and Figures S1–S25.

As shown in Table 2 and Figures S26–S65, high rates of resistance to amoxicillin were observed in samples from all sources (humans 70.5%, 95% CI 57.5%–81%; animals 96%, 95% CI 76%–99%; and food/environment 58.4%, 95% CI 51.7%–65%). Human isolates had very low rates of resistance to colistin (0.8%, 95% CI 0.2%–3.8%), which were the lowest resistance rates across all antimicrobials and isolation sources.

Prevalence of antibiotic resistance in *E. coli* isolates using MIC

As shown in Figure 3, Table 3, and Figures S66–S87 and S89–S90, in *E. coli* strains isolated from humans, the lowest resistance rate was for imipenem (0.1%, 95% CI 0–0.3%) and the highest for amoxicillin (53.4%, 95% CI 22%–82.3%; Table 3 and Figure S91). In *E. coli* strains isolated from animals, the lowest and highest resistance rates were for colistin (0.1%, 95% CI 0–2%) and tetracycline (60%, 95% CI 50%–72.5%), respectively. In *E. coli* strains isolated from food and environmental sources, resistance to imipenem, cefotaxime, and ceftazidime was 1% (95% CI 0.1%–14.5%) and for nalidixic acid 53% (95% CI 39%–67%).

Prevalence of ciprofloxacin resistance in *E. coli* strains isolated from human

Ciprofloxacin was the most reported antibiotic used for *E. coli* in the included studies, so we analyzed ciprofloxacin resistance in more detail. In studies that had used DDM or MIC, the prevalence of ciprofloxacin-resistant *E. coli* strains isolated from humans was higher than the isolated resistant strains from animals, food, and environmental sources. The prevalence of ciprofloxacin-resistant clinical human isolates among different countries included in these studies is shown in Figure 4. In the studied countries, Spain had the lowest prevalence of ciprofloxacin resistance (0.4%) and Iran the highest (52%) with the DDM. The US had the lowest

Table 3. Prevalence of antibiotic resistance in human, animal, food/environment *E. coli* isolates with MIC method

Antibiotic	HUMAN ISOLATES				ANIMAL ISOLATES				FOOD/ENVIRONMENT ISOLATES			
	% PP (CI 95%)	n/N	N of study	I ² (%) P	% PP (CI 95%)	n/N	N of study	I ² (%) P	% PP (CI 95%)	n/N	N of study	I ² (%) P
CL	7.8 (6-10.4)	44/616	3	0.16	0.1 (0-2)	0/400	1	1	-	-	-	-
CIP	7.7 (3.7-15.4)	1288/9899	18	0	7.5 (3.7-14.4)	956/7400	15	0	5.7 (1-26.8)	64/550	4	0
TMP	22.2 (10-42)	216/749	8	0	31 (18-48)	437/1481	6	0	23.7 (16-33)	22/93	1	1
SMZ	22.5 (10.5-42.5)	496/3962	3	0.001	38.3 (16-67)	980/3560	3	0	-	-	-	-
CF	13.3 (1.3-63)	144/501	2	0.01	12.5 (4-33)	120/628	3	0	6.5 (4-10.4)	15/232	1	1
AK	0.8 (0-13.6)	95/7660	5	0	7.8 (4-14.5)	513/5977	5	0	2.6 (1-6)	5/225	2	0.5
AUG	4.5 (2-10)	4497/7967	6	0	2.5 (2.1-3)	99 / 4074	5	0.8	12.8 (6-25.6)	6 / 47	1	1
AMX	53.4 (22-82.3)	74 / 164	2	0	30 (6-73)	326 / 676	3	0	11.5 (1-61)	37 / 325	2	0
CFX	3 (1.6-6)	230/8365	8	0	2.5 (0.5-10)	449 / 6011	7	0	6.5 (2-8)	3 / 47	1	1
CTX	0.5 (0.3-0.8)	16/3585	3	0.8	0.5 (0.1-1.7)	2 / 521	2	0.64	1 (0.1-1.4.6)	0 / 47	1	1
CHL	6.6 (3-13.5)	745/8564	12	0	8 (2.523)	1042 / 6497	11	0	13.5 (1.6-60)	98 / 457	3	0
CRO	9 (3-24)	633 / 5593	6	0	12.5 (6-24.5)	1238 / 6790	7	0	1.7 (0.5-5)	3 / 178	1	1
IMP	0.1 (0-0.3)	3/3510	2	0.6	0.3 (0-4.3)	0 / 177	1	1	1 (0.1-1.4.5)	0 / 47	1	1
SXT	11.5 (4.5-26.2)	1594/8468	6	0	8 (1.6-30)	262 / 4455	5	0	34 (22-48.5)	16 / 47	1	1
TET	37.3 (27-48)	1401/5610	15	0	60 (50-72.5)	6289 / 8596	16	0	41 (0.4-92)	189 / 457	3	0
GM	5 (2-12.2)	401 / 8594	12	0	9.5 (3.6-23)	1400 / 7597	11	0	10.5 (20-40.5)	69 / 457	3	0

(Continued)

Table 3. (Continued).

Antibiotic	HUMAN ISOLATES				ANIMAL ISOLATES				FOOD/ENVIRONMENT ISOLATES			
	% PP (CI 95%)	n/N	N of study	I ² (%) P	% PP (CI 95%)	n/N	N of study	I ² (%) P	% PP (CI 95%)	n/N	N of study	I ² (%) P
KAN	6.2 (2-17.5)	193/5275	10	0	15 (7.3-29)	1323 / 6477	10	0	17 (4-50)	88 / 457	3	0
NA	6.6 (4-10.6)	252 / 4841	7	0	7 (12.5-18)	657 / 5736	8	0	53 (39-67)	25 / 47	1	1
AMP	33.4 (18.5-52.5)	3128/8564	12	0	31 (17-49.5)	2167 / 6497	11	0	29.5 (5-76.3)	145 / 457	3	0
CAZ	1.3 (0.2-7.5)	33/4032	7	0	0.8 (0.4-1.6)	6 / 1172	4	0	1 (0.1-14.6)	0 / 47	1	1
STR	27.7 (14-47.3)	718/5060	11	0	36 (24-51.5)	1727 / 5527	10	0	4 (2-75)	9 / 232	1	0
MDR	12.6 (4.6-30)	253/4170	3	0	22.2 (21-23.4)	1128/5351	5	0	-	-	-	-
ESBL	42.4 (30.5-55.4)	25/59	1	1	63.2 (60.8-65.6)	1073/1748	2	0	28.6 (15-47.7)	8/28	2	0.77

Abbreviations: MDR, Multidrug Resistant; ESBL, Extended Spectrum β -lactamase; PP, Pooled prevalence; n or N, Number; CL, Colistin; CIP, Ciprofloxacin; TMP, trimethoprim; SMZ, Sulfisoxazole; CF, Cephalothin; AK, Amikacin; AUG, Amoxicillin-clavulanic acid; AMX, amoxicillin; CFX, Cefoxitin; CTX, Cefotaxime; CHL, Chloramphenicol; CRO, Ceftriaxone; IMP, Imipenem; SXT, Trimethoprim-sulfamethoxazole; TET, Tetracycline, GM, Gentamicin; KAN, kanamycin; NA, Nalidixic acid; AMP, Ampicillin; CAZ, Ceftazidime; STR, Streptomycin.




Figure 3 Prevalence of antibiotic resistance in human, animal, food/environment *E. coli* isolates with MIC method.
Abbreviation: MIC, minimum inhibitory concentration.




Figure 4 The global prevalence of ciprofloxacin-resistant clinical (human) isolates with DDM and MIC method.
Abbreviations: MIC, minimum inhibitory concentration; DDM, disc diffusion method.

prevalence of ciprofloxacin resistance (0.01%) and Thailand the highest (43%) on MIC. The prevalence of ciprofloxacin-resistant clinical (human) isolates in WHO regional offices with MIC is shown in Figure 5. Our analyses indicated that among WHO regional offices, America and Southeast Asia (0.008% and 43%, respectively) had the lowest and highest

prevalence rates of ciprofloxacin resistance in human isolates using MIC. Overall, results showed that antibiotic resistance in American and European countries is lower than other regions of the world. Subgroup analysis from 2000 to 2018 also indicated a significant increase in ciprofloxacin resistance (Figures 6 and S88).




Figure 5 The prevalence of ciprofloxacin-resistant clinical (human) isolates in WHO regional offices with MIC method.

Discussion

The prevalence of antibiotic resistance in *E. coli* strains simultaneously isolated from human, animal, food, and environment samples from 2000 to 2018 were assessed in this meta-analysis. To our knowledge, the present study is the first comprehensive systematic review on the prevalence of antimicrobial resistance in *E. coli* from different sources. We hope presenting these data helps to prevent the spread of antimicrobial resistance by giving an appropriate vision of *E. coli* drug-resistance patterns in different regions of the world. Based on the meta-analysis results in this study, overall MDR prevalence in human, environmental, and animal *E. coli* isolates was 22%, 31.3%, and 5.7%, respectively, using the DDM. MIC results showed that rates of MDR *E. coli* isolates in humans and animals were 12.6% and 22.2%, respectively. Comparison of MDR *E. coli* strains isolated from different sources showed higher prevalence in animal and environmental sources than humans. The prevalence of ESBL-producing *E. coli* based on MIC in human, animal, and environmental/food isolates was 42.4%, 63.2%, and 28.6%, respectively. The

prevalence of ESBL-producing *E. coli* based on the DDM in human, animal, and environmental/food isolates was 13%, 26.3%, and 25%, respectively. The prevalence of ESBL antibiotic resistance in animal isolates was higher than in human isolates. Furthermore, there was high pooled prevalence of ESBL-producing *E. coli* using MIC, but this was low using the DDM. The uncontrolled use of antibiotics in domestic animals, as well as dietary supplements, could be one of the main reasons for high antimicrobial resistance in animal isolates in some countries.¹⁹ In several countries, such as the Netherlands, nearly 300,000 kg of antibiotics are used every year in the treatment of animals, and this can be considered a possible reason for the emergence of extensive antimicrobial resistance.²⁰ In addition, colonization of healthy adult workers with ESBL-producing *E. coli* may be related to consumption of food and water contaminated with ESBL-producing bacteria.⁵ However, Boonyasiri et al reported that ESBL-producing *E. coli* was found in the food from a market near a factory where stool samples were collected from workers.⁵ Leading antibiotic-resistance




Figure 6 Subgroup analyses of ciprofloxacin-resistant clinical (human) isolates with the MIC method from 2000–2018. **Abbreviation:** MIC, minimum inhibitory concentration.

issues may include indiscriminate use of antibiotics, poor hygiene and other preventive measures in veterinary medicine, insufficient staff training, deficiencies in health centers and infection-control programs in hospitals, and lack of proper management steps in animal farms, which may lead to a high prevalence of ESBL-producing *E. coli* isolates in animal (63%) and human samples (42%).

The prevalence of ciprofloxacin-resistant *E. coli* strains isolated from human with both the DDM and MIC was higher than counterparts isolated from animals, food, or the environment. There was very low pooled prevalence of cefotaxime and ceftazidime resistance in all sample types when tested using MIC (0.5%–1% and 0.8%–1.3%, respectively), but cefotaxime and ceftazidime resistance were much higher with the DDM (31.2%–58% and 10%–57.4%, respectively). Moreover, the prevalence of amoxicillin resistance in animal samples with the DDM was very high (96%), but amoxicillin resistance was lower with MIC (30%).

The main limitation for the current review is the lack of comprehensive studies in different regions of the world. The limited number of studies reporting drug resistance from different sources was another restriction. Split meta-regression, subgroup, and sensitivity analyses to detect the sources of

heterogeneity, publication bias, and heterogeneity must be considered when interpreting the outcomes reported here.

For future direction and supporting the practice of evidence-based medicine, more notifications on *E. coli*-resistance status isolated from different sources (human, animal, and environment or food specimens) are needed. Such studies could enhance our knowledge of antibiotic-resistance status for *E. coli* and help us to provide prevention protocols to reduce the occurrence of resistant strains.

Conclusion

Analyses showed prevalence of drug resistance in different sources and documented increase in *E. coli* drug resistance. Our data demonstrated the evolution of antibiotic resistance and helped to describe drug-resistance prevalence in modern *E. coli* strains. Moreover, the results showed that the prevalence of ESBL antibiotic resistance and MDR *E. coli* strains in animal isolates was higher than in human isolates. According to our findings, systematic surveillance of hospital-associated infections, proper monitoring of disposal processes in hospitals, monitoring the use of antibiotics in animals, monitoring and evaluation of antibiotic-sensitivity patterns, and preparation of reliable antibiotic strategies may

ease more corrective actions for the inhibition and control of *E. coli* infections in different parts of the world.

Author contributions

TA conceived and designed the study, AP and TA performed the study, MJN analyzed the data, and AP, MJN and TA wrote the paper and participated in data analysis and manuscript editing.

Acknowledgments

We greatly appreciate the input from Professor Marc William Allard (Division of Microbiology, Office of Regular Science, Center for Food Safety and Applied Nutrition, US Food and Drug Administration, College Park, MD, USA) for his collaboration with us as an expert and native English speaker for revision of the manuscript and his helpful comments.

Disclosure

The authors report no conflicts of interest in this work.

References

- Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *BMJ*. 2016;352:i939. doi:10.1136/bmj.i1717
- Bonnedahl J, Drobní P, Johansson A, et al. Characterization, and comparison, of human clinical and black-headed gull (*Larus ridibundus*) extended-spectrum β -lactamase-producing bacterial isolates from Kalmar, on the southeast coast of Sweden. *J Antimicrob Chemother*. 2010;65(9):1939–1944. doi:10.1093/jac/dkq222
- Bhoomika SS, Patyal A, Gade NE. Occurrence and characteristics of extended-spectrum β -lactamases producing *Escherichia coli* in foods of animal origin and human clinical samples in Chhattisgarh, India. *Vet World*. 2016;9(9):996. doi:10.14202/vetworld.2016.996-1000
- Yang C, Lin M, Liao P, et al. Comparison of antimicrobial resistance patterns between clinical and sewage isolates in a regional hospital in Taiwan. *Lett Appl Microbiol*. 2009;48(5):560–565. doi:10.1111/j.1472-765X.2009.02572.x
- Boonyasiri A, Tangkoskul T, Seenama C, Saiyarin J, Tiengrim S, Thamlikitkul V. Prevalence of antibiotic resistant bacteria in healthy adults, foods, food animals, and the environment in selected areas in Thailand. *Pathog Glob Health*. 2014;108(5):235–245. doi:10.1179/204773214Y.0000000148
- Hashemi B, Abdollahi M, Rafiei A, et al. The comparison of MAMA PCR and SSCP PCR to study chromosomal resistance against Ciprofloxacin and Nalidixic acid in *Escherichia coli* and *Klebsiella pneumoniae*. *Microb Pathog*. 2018;120:181–186. doi:10.1016/j.micpath.2018.05.005
- Pormohammad A, Pouriran R, Azimi H, Goudarzi M. Prevalence of integron classes in Gram-negative clinical isolated bacteria in Iran: a systematic review and meta-analysis. *Iran J Basic Med Sci*. 2019;22(2):118–127.
- Sahoo KC, Tamhankar AJ, Sahoo S, Sahu PS, Klintz SR, Lundborg CS. Geographical variation in antibiotic-resistant *Escherichia coli* isolates from stool, cow-dung and drinking water. *Int J Environ Res Public Health*. 2012;9(3):746–759. doi:10.3390/ijerph9030746
- Azimi T, Nasiri MJ, Chirani AS, Pouriran R, Dabiri H. The role of bacteria in the inflammatory bowel disease development: a narrative review. *APMIS*. 2018;126(4):275–283. doi:10.1111/apm.12814
- Gholizadeh P, Mahallei M, Pormohammad A, et al. Microbial balance in the intestinal normal microbiome and its association with diabetes, obesity and allergic disease. *Microb Pathog*. 2018.
- Reinthal FF, Galler H, Feierl G, et al. Resistance patterns of *Escherichia coli* isolated from sewage sludge in comparison with those isolated from human patients in 2000 and 2009. *J Water Health*. 2013;11(1):13–20. doi:10.2166/wh.2012.207
- Carattoli A. Animal reservoirs for extended spectrum β -lactamase producers. *Clin Microbiol Infect*. 2008;14:117–123. doi:10.1111/j.1469-0691.2007.01851.x
- Pormohammad A, Mohtavinejad N, Gholizadeh P, et al. Global estimate of gastric cancer in *Helicobacter pylori*-infected population: a systematic review and meta-analysis. *J Cell Physiol*. 2019;234(2):1208–1218. doi:10.1002/jcp.27114
- Pormohammad A, Nasiri MJ, Riahi SM, Fallah F. Human immunodeficiency virus in patients with tuberculous meningitis: systematic review and meta-analysis. *Trop Med Int Health*. 2018;23(6):589–595. doi:10.1111/tmi.13059
- Pormohammad A, Riahi S-M, Nasiri MJ, et al. Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: a systematic review and meta-analysis. *J Infect*. 2017;74(6):545–554. doi:10.1016/j.jinf.2017.02.012
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med*. 2009;151(4):W-65–W-94. doi:10.7326/0003-4819-151-4-200908180-00136
- Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews: addressing questions of prevalence. *Int J Health Policy Manag*. 2014;3:123–128. doi:10.15171/ijhpm.2014.71
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies. *J Natl Cancer Inst*. 1959;22(4):719–748.
- Alali WQ, Scott H, Harvey R, Norby B, Lawhorn D, Pillai S. Longitudinal study of antimicrobial resistance among *Escherichia coli* isolates from integrated multisite cohorts of humans and swine. *Appl Environ Microbiol*. 2008;74(12):3672–3681. doi:10.1128/AEM.02624-07
- Paltansing S, Vlot JA, Kraakman ME, et al. Extended-spectrum β -lactamase-producing Enterobacteriaceae among travelers from the Netherlands. *Emerg Infect Dis*. 2013;19(8):1206. doi:10.3201/eid1909.130682
- Moura A, Araújo S, Alves MS, Henriques I, Pereira A, Correia A. The contribution of *Escherichia coli* from human and animal sources to the integron gene pool in coastal waters. *Front Microbiol*. 2014;5:419. doi:10.3389/fmicb.2014.00547
- Kazemnia A, Ahmadi M, Dilmaghani M. Antibiotic resistance pattern of different *Escherichia coli* phylogenetic groups isolated from human urinary tract infection and avian colibacillosis. *Iran Biomed J*. 2014;18(4):219.
- Mora A, Blanco JE, Blanco M, et al. Antimicrobial resistance of Shiga toxin (verotoxin)-producing *Escherichia coli* O157: H7 and non-O157 strains isolated from humans, cattle, sheep and food in Spain. *Res Microbiol*. 2005;156(7):793–806. doi:10.1016/j.resmic.2005.03.006

24. Liu B, Wu H, Zhai Y, et al. Prevalence and molecular characterization of *oqxAB* in clinical *Escherichia coli* isolates from companion animals and humans in Henan Province, China. *Antimicrob Resist Infect Control*. 2018;7(1):18. doi:10.1186/s13756-018-0310-8
25. Van den Bogaard A, London N, Driessen C, Stobberingh E. Antibiotic resistance of faecal *Escherichia coli* in poultry, poultry farmers and poultry slaughterers. *J Antimicrob Chemother*. 2001;47(6):763–771.
26. Sidjabat HE, Townsend KM, Lorentzen M, et al. Emergence and spread of two distinct clonal groups of multidrug-resistant *Escherichia coli* in a veterinary teaching hospital in Australia. *J Med Microbiol*. 2006;55(8):1125–1134. doi:10.1099/jmm.0.46598-0
27. Maciuca IE, Williams NJ, Tuchilus C, et al. High prevalence of *Escherichia coli*-producing CTX-M-15 extended-spectrum beta-lactamases in poultry and human clinical isolates in Romania. *Microb Drug Resist*. 2015;21(6):651–662. doi:10.1089/mdr.2014.0248
28. Johnson JR, Sannes MR, Croy C, et al. Antimicrobial drug-resistant *Escherichia coli* from humans and poultry products, Minnesota and Wisconsin, 2002–2004. *Emerg Infect Dis*. 2007;13(6):838. doi:10.3201/eid1306.061576
29. Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended-spectrum cephalosporins and cephamycins among *Escherichia coli* isolates from animals and humans. *J Infect Dis*. 2003;188(5):759–768. doi:10.1086/377455
30. Wang J, Zhi C-P, Chen X-J, et al. Characterization of *oqxAB* in *Escherichia coli* isolates from animals, retail meat, and human patients in Guangzhou, China. *Front Microbiol*. 2017;8:1982. doi:10.3389/fmicb.2017.01982
31. Platell JL, Cobbold RN, Johnson JR, Trott DJ. Clonal group distribution of fluoroquinolone-resistant *Escherichia coli* among humans and companion animals in Australia. *J Antimicrob Chemother*. 2010;65(9):1936–1938. doi:10.1093/jac/dkq236
32. Hernandez J, Johansson A, Stedt J, et al. Characterization and comparison of extended-spectrum β -lactamase (ESBL) resistance genotypes and population structure of *Escherichia coli* isolated from Franklin's gulls (*Leucophaeus pipixcan*) and humans in Chile. *PLoS One*. 2013;8(9):e76150. doi:10.1371/journal.pone.0076150
33. Alroy K, Ellis JC. Pilot study of antimicrobial-resistant *Escherichia coli* in herring gulls (*Larus argentatus*) and wastewater in the north-eastern United States. *J Zoo Wildl Med*. 2011;42(1):160–163. doi:10.1638/2010-0130.1
34. Stenske KA, Bemis DA, Gillespie BE, et al. Comparison of clonal relatedness and antimicrobial susceptibility of fecal *Escherichia coli* from healthy dogs and their owners. *Am J Vet Res*. 2009;70(9):1108–1116. doi:10.2460/ajvr.70.9.1108
35. Wang L, Nakamura H, Kage-Nakadai E, Hara-Kudo Y, Nishikawa Y. Comparison by multilocus variable-number tandem repeat analysis and antimicrobial resistance among atypical enteropathogenic *Escherichia coli* strains isolated from food samples and human and animal faecal specimens. *J Appl Microbiol*. 2017;122(1):268–278. doi:10.1111/jam.13322
36. Purohit MR, Chandran S, Shah H, Diwan V, Tamhankar AJ, Stålsby Lundborg C. Antibiotic resistance in an Indian rural community: a 'One-Health' observational study on commensal coliform from humans, animals, and water. *Int J Environ Res Public Health*. 2017;14(4):386. doi:10.3390/ijerph14040386
37. Sannes MR, Kuskowski MA, Johnson JR. Antimicrobial resistance of *Escherichia coli* strains isolated from urine of women with cystitis or pyelonephritis and feces of dogs and healthy humans. *J Am Vet Med Assoc*. 2004;225(3):368–373.
38. Miles TD, McLaughlin W, Brown PD. Antimicrobial resistance of *Escherichia coli* isolates from broiler chickens and humans. *BMC Vet Res*. 2006;2(1):7. doi:10.1186/1746-6148-2-7
39. Sabaté M, Prats G, Moreno E, Ballesté E, Blanch AR, Andreu A. Virulence and antimicrobial resistance profiles among *Escherichia coli* strains isolated from human and animal waste water. *Res Microbiol*. 2008;159(4):288–293. doi:10.1016/j.resmic.2008.02.001
40. Dhaka P, Vijay D, Vergis J, et al. Genetic diversity and antibiogram profile of diarrhoeagenic *Escherichia coli* pathotypes isolated from human, animal, foods and associated environmental sources. *Infect Ecol Epidemiol*. 2016;6(1):31055. doi:10.3402/iee.v6.31055
41. Pasquali F, Lucchi A, Braggio S, et al. Genetic diversity of *Escherichia coli* isolates of animal and environmental origins from an integrated poultry production chain. *Vet Microbiol*. 2015;178(3–4):230–237. doi:10.1016/j.vetmic.2015.05.007
42. Beier RC, Franz E, Bono JL, et al. Disinfectant and antimicrobial susceptibility profiles of the big six non-O157 shiga toxin-producing *Escherichia coli* strains from food animals and humans. *J Food Prot*. 2016;79(8):1355–1370. doi:10.4315/0362-028X.JFP-15-600
43. Koczura R, Mokracka J, Jabłońska L, Gozdecka E, Kubek M, Kaznowski A. Antimicrobial resistance of integron-harboring *Escherichia coli* isolates from clinical samples, wastewater treatment plant and river water. *Sci Total Environ*. 2012;414:680–685. doi:10.1016/j.scitotenv.2011.10.036
44. Sayah RS, Kaneene JB, Johnson Y, Miller R. Patterns of antimicrobial resistance observed in *Escherichia coli* isolates obtained from domestic-and wild-animal fecal samples, human septage, and surface water. *Appl Environ Microbiol*. 2005;71(3):1394–1404. doi:10.1128/AEM.71.3.1394-1404.2005
45. Scott H, Campbell L, Harvey R, et al. Patterns of antimicrobial resistance among commensal *Escherichia coli* isolated from integrated multi-site housing and worker cohorts of humans and swine. *Foodborne Pathog Dis*. 2005;2(1):24–37. doi:10.1089/fpd.2005.2.24
46. Šeputienė V, Povilonis J, Ružauskas M, Pavilonis A, Sužiedėlienė E. Prevalence of trimethoprim resistance genes in *Escherichia coli* isolates of human and animal origin in Lithuania. *J Med Microbiol*. 2010;59(3):315–322. doi:10.1099/jmm.0.015008-0
47. Lei T, Tian W, He L, et al. Antimicrobial resistance in *Escherichia coli* isolates from food animals, animal food products and companion animals in China. *Vet Microbiol*. 2010;146(1–2):85–89. doi:10.1016/j.vetmic.2010.04.025
48. Unno T, Han D, Jang J, et al. High diversity and abundance of antibiotic-resistant *Escherichia coli* isolated from humans and farm animal hosts in Jeonnam Province, South Korea. *Sci Total Environ*. 2010;408(17):3499–3506. doi:10.1016/j.scitotenv.2010.04.046
49. Unno T, Han D, Jang J, et al. Genotypic and phenotypic trends in antibiotic resistant pathogenic *Escherichia coli* isolated from humans and farm animals in South Korea. *Microbes Environ*. 2011;26(3):198–204.
50. Edge TA, Hill S. Occurrence of antibiotic resistance in *Escherichia coli* from surface waters and fecal pollution sources near Hamilton, Ontario. *Can J Microbiol*. 2005;51(6):501–505. doi:10.1139/w05-028
51. Thorsteinsdóttir T, Haraldsson G, Fridriksdóttir V, Kristinsson K, Gunnarsson E. Prevalence and genetic relatedness of antimicrobial-resistant *Escherichia coli* isolated from animals, foods and humans in Iceland. *Zoonoses Public Health*. 2010;57(3):189–196. doi:10.1111/j.1863-2378.2009.01256.x
52. Hancock V, Nielsen EM, Krag L, Engberg J, Klemm P. Comparative analysis of antibiotic resistance and phylogenetic group patterns in human and porcine urinary tract infectious *Escherichia coli*. *APMIS*. 2009;117(11):786–790. doi:10.1111/j.1600-0463.2009.02542.x
53. Winokur P, Vonstein D, Hoffman L, Uhlenhopp E, Doern G. Evidence for transfer of CMY-2 AmpC β -Lactamase Plasmids between *Escherichia coli* and *Salmonella* isolates from food animals and humans. *Antimicrob Agents Chemother*. 2001;45(10):2716–2722. doi:10.1128/AAC.45.10.2716-2722.2001

54. Sáenz Y, Zarazaga M, Briñas L, Lantero M, Ruiz-Larrea F, Torres C. Antibiotic resistance in *Escherichia coli* isolates obtained from animals, foods and humans in Spain. *Int J Antimicrob Agents*. 2001;18(4):353–358.
55. Kang HY, Jeong YS, Oh JY, et al. Characterization of antimicrobial resistance and class 1 integrons found in *Escherichia coli* isolates from humans and animals in Korea. *J Antimicrob Chemother*. 2005;55(5):639–644. doi:10.1093/jac/dki076

Supplementary material

Table S1 Characterization of included studies

First author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	End Point of 8
Adhiratha	1	1	0	1	1	0	1	5
Alali2008	1	1	1	2	1	1	1	8
AlexandraMoura	1	1	1	2	1	0	1	7
Ali Kazemnia	0	1	0	1	1	1	1	5
Azucena Mora	1	1	1	1	0	1	1	6
Baoguang	1	1	1	1	1	0	1	6
Bhoomika	0	1	1	0	1	0	1	4
Bogaard2001	1	1	1	1	1	0	1	6
Hanna E. Sidjabat	0	1	1	1	1	0	1	5
Iuliana E. Maciucă	0	1	1	1	1	1	1	6
James	1	1	1	2	1	1	1	8
Jing Wang	1	1	1	1	0	1	1	6
Joanne L. Platell	0	1	1	0	0	0	1	3
Jorge Hernandez	0	1	0	1	1	1	1	5
Karen Alroy	0	0	1	0	1	0	1	3
Katherine A. Stenske	1	1	1	2	1	1	1	8
Krushna Chandra	1	1	1	1	1	0	1	6
L. Wang	1	1	1	1	0	1	1	6
Manju Raj Purohit	1	1	1	1	1	1	1	7
Mark R. Sannes	1	1	1	2	1	1	1	8
Miles2006-1	1	1	1	1	0	1	1	6
Miles2006-2	1	1	1	1	0	1	1	6
Montserrat Sabate	1	1	1	1	1	0	1	6
Pankaj Dhaka	1	1	1	1	0	1	1	6
Adhiratha	1	1	0	1	1	0	1	5
Adhiratha Boonyasiri	1	1	0	1	1	0	1	5
TATSUYA	1	1	1	1	0	0	1	5
Pasquali2015	1	1	1	1	0	0	1	5
ROSS	0	1	1	1	0	1	1	5
Ryszard Koczura	1	1	1	2	1	1	1	8
Sayah2005	1	1	0	1	1	0	1	5
SCOTT	1	1	1	2	0	1	1	7
Thomas	1	0	0	1	0	0	1	3
Thorsteinsdottir	0	1	1	1	0	1	1	5
VIKTORIA	0	1	1	1	0	0	1	4
WINOKUR	0	1	1	1	1	0	1	5
Yolanda	0	1	1	0	1	0	1	4
Young	0	1	1	1	1	1	1	6

Abbreviations: ADM, agar dilution method; DDM, disk diffusion method; BMD, broth microdilution.

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>